Alternaria Alternata (Alt a 6) IgE

If you have eczema, asthma, or stubborn breathing symptoms that flare in damp or moldy environments, the question of which exact mold proteins your body is reacting to actually matters. Alt a 6 (Alternaria alternata allergen 6) is one of several specific molecules from this mold that your immune system can target, and its presence in your blood points to a particular subset of mold-driven allergy.

This test measures a secondary Alternaria component, not the dominant one. Most people with true Alternaria allergy react to Alt a 1, the major marker. Alt a 6 shows up in a smaller share of patients overall, but in that group it tends to flag a specific pattern: eczema that overlaps with asthma. A note on naming: older research from around 2000 referred to the Alternaria enolase as Alt a 5; the WHO/IUIS allergen nomenclature later reassigned it to Alt a 6, so older literature on "Alt a 5 enolase" describes the same protein.

What Alt a 6 Actually Is

Alt a 6 is a fungal enzyme called enolase. It is a protein made by the mold itself, and it cross-reacts with similar enolase proteins from other fungal species. When your immune system encounters this protein and decides it is a threat, your B cells (the immune cells that make antibodies) produce IgE (immunoglobulin E, the antibody class that drives allergic reactions) specifically shaped to recognize it. This test measures those antibodies in your blood.

Alt a 1 is the clearly dominant marker, while Alt a 6 has been described as a secondary or minor allergen in most cohorts, though older work by Breitenbach and colleagues reported that around half of enolase-reactive patients showed strong responses to recombinant fungal enolases, so its importance can vary by population. In one Spanish cohort of patients receiving Alternaria immunotherapy, only about 12.5% had IgE against Alt a 4 or Alt a 6, compared with 98.4% who had IgE against Alt a 1. That figure comes from a specific treatment cohort rather than the general population, but it captures the broad pattern: a negative Alt a 6 result does not rule out Alternaria allergy. It tells you something more specific about which molecules your immune system targets.

This Is an Emerging Research Marker

Alt a 6 IgE is not a standalone clinical decision tool. Standardized cutpoints do not exist for individual disease decisions, and the test is most useful as part of broader allergy profiling done through multiplex platforms like ALEX2 or ImmunoCAP ISAC. Interpretation requires context: symptoms, exposure history, and other allergy testing.

Atopic Dermatitis with Asthma Overlap

The clearest finding for Alt a 6 IgE in human research is its link to a specific phenotype: eczema with coexisting asthma. In a study of 100 atopic dermatitis patients using the ALEX2 multiplex panel, high levels of IgE against Alt a 6 were significantly more frequent in those who also had bronchial asthma.

A follow-up ALEX2 analysis in 100 atopic dermatitis patients from the same research group reinforced this pattern: enolase from Alternaria stood out as an important molecular component in patients with concomitant asthma. Because both studies come from a single group using the same platform and cohort size, they are best read as one consistent line of evidence rather than two independent confirmations. If you have eczema and find your skin and breathing flare together, this marker can help characterize whether mold sensitization is part of the picture.

Asthma and Mold-Driven Airway Disease

Alternaria sensitization in general is linked to asthma onset, severity, and a phenotype called type 2 high asthma, which is the form most responsive to allergy-targeted treatments. In a study of 582 asthmatic patients, those with Alternaria-related type 2 high asthma had higher total and specific IgE levels and were more often sensitized to multiple allergens at once compared with type 2 low patients. That study measured sensitization with whole Alternaria extract rather than the Alt a 6 component specifically.

Most of this clinical signal comes from Alt a 1 testing and whole-extract testing, not Alt a 6. Alt a 6 adds incremental information about a subset of patients whose mold-related airway disease would be incompletely characterized by extract-level testing alone.

Allergic Rhinitis and Nasal Disease

Alternaria sensitization is associated with allergic rhinitis and rhinoconjunctivitis, particularly in regions where the mold is prevalent. In one Spanish cohort of 1,156 patients, Alternaria was the most prevalent source of fungal sensitization. Again, the dominant marker is Alt a 1; Alt a 6 plays a supporting role in identifying the full sensitization profile.

Why a Standard Allergy Panel May Miss This

A normal result on a basic inhalant allergy panel does not mean Alt a 6 is normal. Standard panels typically include whole Alternaria extract or sometimes Alt a 1, but rarely Alt a 6. If you have eczema with asthma overlap and your routine panel looks clean, this molecular component test can reveal sensitization that the broader extract testing diluted or missed. The correlation between skin prick tests and specific IgE for Alternaria is only weak to moderate, so testing methods do not always agree.

Why One Reading Is Not Enough

Allergen-specific IgE levels can shift over time as exposure changes, as your immune system responds to seasonal patterns, and as you undergo treatments like allergen immunotherapy. A single reading captures one moment. Tracking your trend matters more than fixating on any single number, particularly because Alt a 6 is a research-grade marker without firmly established clinical thresholds.

A practical approach: get a baseline reading alongside Alt a 1 and total IgE, then retest in 6 to 12 months if you start an intervention like immunotherapy or make significant changes to your indoor environment. If you are stable and asymptomatic, annual monitoring is reasonable. The value lies in seeing whether your sensitization is rising, falling, or holding steady, not in chasing a specific target number.

When Results Can Be Misleading

Several factors can distort a single Alt a 6 IgE reading or make interpretation tricky:

• Cross-reactivity with other fungal enolases: because enolase proteins are highly conserved across many fungal species (including Cladosporium, Saccharomyces, and Candida), a positive Alt a 6 result may reflect sensitization to related fungal enolases rather than Alternaria specifically.
• Platform differences: multiplex panels like ALEX2 and ImmunoCAP can give slightly different values for the same sample. Comparing across platforms without noting the assay used can mislead.
• Polysensitization: many Alternaria-sensitized patients also react to dust mites, pollens, and pet dander. Attributing symptoms to Alt a 6 specifically requires careful clinical correlation.
• Regional exposure variation: in some regions Alternaria sensitization is common and clinically important; in others, like Finland, it is rare and of minor clinical importance. Your geography matters.
• Older versus newer naming: literature published before the WHO/IUIS reassignment refers to this enolase as Alt a 5. If you are reading older papers, the same protein is being discussed.

What to Do With an Unexpected Result

If your Alt a 6 IgE comes back positive, the next step is not to assume Alternaria is driving all your symptoms. The decision pathway looks like this: pair the result with Alt a 1 IgE (the major marker), total IgE, and a broader inhalant panel to map your full sensitization profile. If you have eczema with overlapping asthma symptoms, consider a referral to an allergist for component-resolved diagnostic interpretation. If immunotherapy is on the table, Alt a 1 status drives that decision more than Alt a 6.

If your result is negative but you suspect mold-related symptoms, do not stop there. Alt a 1 testing is the dominant marker for Alternaria sensitization, and negative Alt a 6 alone does not rule out clinically meaningful mold allergy. Pursue broader testing including Alt a 1, total Alternaria extract IgE, and potentially nasal or bronchial provocation testing when symptoms strongly suggest mold-driven disease.